J&J, Castleman Disease Collaborative Network deal

Non-profit CDCN and the Janssen Research & Development LLC unit of Johnson & Johnson partnered to conduct a proteomics study of idiopathic multicentric Castleman's disease (iMCD), a CD subtype. The partners will measure levels of about 1,300 molecules in serum samples from about 100 iMCD patients. By identifying molecules with altered serum levels in iMCD patients, the partners hope to reduce the time needed to diagnose iMCD and identify potential new targets for treatment. Janssen will fund "a significant portion" of the project and contribute serum samples. ...